{"product_id":"understanding-bile-acid-diarrhoea-expert-guidance-on-diagnosis-and-treatment","title":"Understanding Bile Acid Diarrhoea: Expert Guidance on Diagnosis and Treatment","description":"\u003cp\u003eBile acid diarrhoea (BAD) is a common yet frequently underdiagnosed cause of chronic digestive symptoms, affecting patients with conditions ranging from irritable bowel syndrome with diarrhoea to post-surgical digestive changes. This expert survey of 21 UK gastroenterologists, all of whom have published research on the condition, reveals strong consensus on best practices: the SeHCAT test is the preferred diagnostic tool, bile acid sequestrants are highly effective treatments, and most patients with a positive test respond well to therapy. The findings provide clear guidance for doctors and hope for the many patients who currently experience years of diagnostic delay and uncertainty.\u003c\/p\u003e\n\n\u003ch1\u003eUnderstanding Bile Acid Diarrhoea: Expert Guidance on Diagnosis and Treatment\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: What Is Bile Acid Diarrhoea?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow This Expert Survey Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#terminology\"\u003eWhat Should This Condition Be Called?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#associated\"\u003eRecognised Associated Conditions\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#symptoms\"\u003eSymptoms That Point to Bile Acid Diarrhoea\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#diagnosis\"\u003eDiagnostic Tests: How BAD Is Confirmed\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#treatment\"\u003eTreatment Decisions and Expected Response Rates\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#medications\"\u003eMedication Doses and Administration\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#followup\"\u003eFollow-Up and Improving Patient Experience\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#discussion\"\u003eExpert Discussion: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eBile acid diarrhoea is common but underdiagnosed, often delayed over 5 years.\u003c\/li\u003e\n\u003cli\u003eSeHCAT is the preferred test; all 21 surveyed experts use it.\u003c\/li\u003e\n\u003cli\u003eTypical symptoms: frequent loose stools, urgency, and faecal incontinence.\u003c\/li\u003e\n\u003cli\u003eBile acid sequestrants work well; severe cases respond in over 70%.\u003c\/li\u003e\n\u003cli\u003eAsk about BAD if you have diarrhoea after gallbladder removal or ileal surgery.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: What Is Bile Acid Diarrhoea?\u003c\/h2\u003e\n\n\u003cp\u003eBile acids are digestive fluids produced by the liver that help break down fats in the small intestine. Normally, most of these bile acids are reabsorbed in the final section of the small intestine (the terminal ileum) and recycled back to the liver. When this process goes wrong, excess bile acids spill into the colon (large intestine), where they cause water and electrolytes to be secreted into the bowel. The result is a range of distressing digestive symptoms.\u003c\/p\u003e\n\n\u003cp\u003eThis condition has been recognised for over 50 years, originally called \"cholerheic enteropathy.\" Today it is known by several names, including bile acid diarrhoea (BAD), bile acid malabsorption (BAM), and bile salt malabsorption. The scientific understanding has evolved considerably, and the condition is now recognised as far more common than previously thought.\u003c\/p\u003e\n\n\u003cp\u003eThere are two main categories of BAD. \u003cstrong\u003eSecondary BAD\u003c\/strong\u003e occurs when there is a clear underlying cause, such as:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eSurgical removal of part of the ileum (ileal resection), often for Crohn's disease\u003c\/li\u003e\n  \u003cli\u003eActive Crohn's disease affecting the small intestine\u003c\/li\u003e\n  \u003cli\u003eCancer chemotherapy\u003c\/li\u003e\n  \u003cli\u003ePelvic irradiation (radiation therapy to the pelvic area)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003ePrimary or idiopathic BAD\u003c\/strong\u003e occurs when no such cause can be found. This form is common and represents a significant subset of people diagnosed with chronic functional diarrhoea or irritable bowel syndrome with predominant diarrhoea (IBS-D). In most of these patients, there is no actual defect in bile acid absorption. Instead, the problem is that the liver produces too many bile acids. This has been demonstrated by studies showing increased blood levels of a bile acid precursor called 7α-OH-4-cholesten-3-one (abbreviated as C4) and impaired feedback from a hormone called fibroblast growth factor 19 (FGF19), which is produced in the ileum.\u003c\/p\u003e\n\n\u003cp\u003eOne particularly troubling finding from patient surveys is the \u003cstrong\u003epoor professional recognition\u003c\/strong\u003e of this condition. Many patients experience diagnostic delays exceeding 5 years, enduring persistent symptoms while searching for answers. There is a large unmet need in symptom control, and many patients are left without effective treatment for years.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow This Expert Survey Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eTo establish what current best practice actually looks like, the UK Bile Acid Related Diarrhoea Network (UK-BARDN) was established in 2017 as a forum for researchers who had recently published work on BAD\/BAM. The research team identified areas of debate in diagnosis and management and developed a survey consisting of 24 questions.\u003c\/p\u003e\n\n\u003cp\u003eThe survey was distributed online using Survey Monkey at the end of 2018 to \u003cstrong\u003e21 clinicians\u003c\/strong\u003e who were members of UK-BARDN. All of these clinicians had published research on BAD. At the time of the survey, \u003cstrong\u003e95% held a consultant post in the NHS\u003c\/strong\u003e (the UK's National Health Service); this has since become 100%. A remarkable \u003cstrong\u003e100% response rate\u003c\/strong\u003e was achieved.\u003c\/p\u003e\n\n\u003cp\u003eThese were not doctors with casual exposure to the condition. When asked how many patients they had diagnosed with BAD:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e85%\u003c\/strong\u003e had diagnosed over \u003cstrong\u003e50 patients\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e48%\u003c\/strong\u003e had diagnosed more than \u003cstrong\u003e100 patients\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn total, the survey represents the collective experience of over 20 British gastroenterologists who have treated more than 1,000 patients with BAD. Statistical comparisons were made using Fisher's exact test, with a p value of 0.05 taken as statistically significant.\u003c\/p\u003e\n\n\u003ch2 id=\"terminology\"\u003eWhat Should This Condition Be Called?\u003c\/h2\u003e\n\n\u003cp\u003eThe terminology for this condition has varied considerably over the years, which can be confusing for patients encountering different terms in medical records, online information, and consultations. The experts were asked whether there was a preferred term:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e57%\u003c\/strong\u003e preferred \"bile acid diarrhoea\" as their first choice\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e14%\u003c\/strong\u003e preferred \"bile acid malabsorption\"\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e29%\u003c\/strong\u003e used either term depending on the clinical circumstances\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eWhen it came to classifying the different types of the condition, \u003cstrong\u003e89%\u003c\/strong\u003e preferred the terms \"primary or secondary\" to describe the cause. The second preference was \"types 1, 2 and 3,\" and the third was \"overproduction or malabsorption.\" This means patients will most likely encounter the terms \"primary BAD\" (no identifiable underlying cause) or \"secondary BAD\" (caused by another condition or surgery).\u003c\/p\u003e\n\n\u003ch2 id=\"associated\"\u003eRecognised Associated Conditions\u003c\/h2\u003e\n\n\u003cp\u003eThe experts were asked which specific conditions they recognised as being associated with a higher incidence of BAD. The majority identified a wide range of conditions, shown here with the percentage of respondents who recognised each association:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eIleal resection (surgical removal of part of the ileum)\u003c\/li\u003e\n  \u003cli\u003eCrohn's disease\u003c\/li\u003e\n  \u003cli\u003eRight hemicolectomy (surgical removal of the right side of the colon)\u003c\/li\u003e\n  \u003cli\u003eCholecystectomy (gallbladder removal)\u003c\/li\u003e\n  \u003cli\u003ePelvic or abdominal radiotherapy\u003c\/li\u003e\n  \u003cli\u003eIrritable bowel syndrome with predominant diarrhoea (IBS-D)\u003c\/li\u003e\n  \u003cli\u003eFunctional bowel disease with diarrhoea\u003c\/li\u003e\n  \u003cli\u003eMicroscopic colitis (a type of bowel inflammation visible only under a microscope)\u003c\/li\u003e\n  \u003cli\u003eBariatric surgery (weight loss surgery)\u003c\/li\u003e\n  \u003cli\u003eSmall intestinal bacterial overgrowth (SIBO)\u003c\/li\u003e\n  \u003cli\u003ePartial gastrectomy (surgical removal of part of the stomach)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis list is important for patients because it highlights that BAD can develop after surgery, after cancer treatment, or alongside other digestive conditions. If you have any of these conditions and experience chronic diarrhoea, BAD should be considered as a possible cause.\u003c\/p\u003e\n\n\u003ch2 id=\"symptoms\"\u003eSymptoms That Point to Bile Acid Diarrhoea\u003c\/h2\u003e\n\n\u003cp\u003eUnderstanding which symptoms should trigger testing for BAD is critical for improving diagnosis rates. The experts were asked which specific symptoms would lead them to consider a diagnostic test. The results are shown in the table below:\u003c\/p\u003e\n\n\u003cstrong\u003eSymptoms routinely leading to consideration of a diagnostic test for BAD:\u003c\/strong\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAlways having loose stools\u003c\/strong\u003e – 86% of respondents\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFrequency of bowel movements greater than 6 times per day\u003c\/strong\u003e – 86%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFrequency of bowel movements 3–6 times per day\u003c\/strong\u003e – 81%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIntermittent loose stools\u003c\/strong\u003e – 76%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFaecal urgency at least weekly\u003c\/strong\u003e (the sudden, intense need to reach a toilet) – 67%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFaecal incontinence at least weekly\u003c\/strong\u003e (accidental leakage of stool) – 62%\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eInterestingly, the majority of experts said they would \u003cstrong\u003enot\u003c\/strong\u003e routinely consider testing for BAD based on several other symptoms, including:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eWeight gain or weight loss combined with loose stools\u003c\/li\u003e\n  \u003cli\u003eVariable loose and hard stools\u003c\/li\u003e\n  \u003cli\u003eAnal faecal soiling (minor leakage without full incontinence)\u003c\/li\u003e\n  \u003cli\u003eBowel frequency of only 1–3 times per day\u003c\/li\u003e\n  \u003cli\u003eAbdominal pain associated with or relieved by defaecation\u003c\/li\u003e\n  \u003cli\u003eSpecific yellow or green coloured stools (a commonly repeated belief that did not hold up in expert practice)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese findings are valuable for patients and GPs alike: if you have persistent loose stools multiple times a day, urgency, or incontinence, it is worth discussing BAD testing with your doctor — even if you have been told your symptoms are \"just IBS.\"\u003c\/p\u003e\n\n\u003ch2 id=\"diagnosis\"\u003eDiagnostic Tests: How BAD Is Confirmed\u003c\/h2\u003e\n\n\u003cp\u003eThe survey asked experts which diagnostic tests they use for BAD. There was a clear winner: \u003cstrong\u003eall respondents (100%) selected the SeHCAT test\u003c\/strong\u003e as a diagnostic test for BAD.\u003c\/p\u003e\n\n\u003ch3\u003eWhat is the SeHCAT test?\u003c\/h3\u003e\n\n\u003cp\u003eThe SeHCAT test (tauroselcholic acid scan) uses a small amount of radioactive material — specifically, 75Se-radiolabelled 23-selena-25-homotaurocholate — attached to a synthetic bile acid. This was developed in the 1980s. The patient swallows a capsule containing this substance, and a special gamma camera measures how much of it is retained in the body over 7 days. A low retention rate means bile acids are leaking into the colon instead of being reabsorbed — confirming the diagnosis of BAD.\u003c\/p\u003e\n\n\u003cp\u003eThe SeHCAT test has been shown to predict response to various treatments, including colestyramine, colestipol, colesevelam, a low-fat diet, and even a medication called obeticholic acid. Its use in the UK has grown substantially, particularly in the last decade.\u003c\/p\u003e\n\n\u003ch3\u003eOther diagnostic tests\u003c\/h3\u003e\n\n\u003cp\u003eBlood tests were also recognised as useful diagnostic tools by a majority of experts, though less commonly than SeHCAT:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFGF19 blood test\u003c\/strong\u003e – recognised by 61%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eC4 blood test\u003c\/strong\u003e – recognised by 57%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTherapeutic trial\u003c\/strong\u003e (giving treatment to see if symptoms improve) – recognised by 47%\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFaecal (stool) bile acid collections are considered unpopular with patients but have been optimised by researchers at the Mayo Clinic in the USA to include the percentage of primary bile acids. It is worth noting that the SeHCAT test is \u003cstrong\u003enot available in the USA\u003c\/strong\u003e and is not licenced there, which has significantly impaired global understanding and recognition of BAD. This limited availability has also hindered the development of new drugs and formal consensus guidelines. The experts in this survey had limited personal experience with faecal bile acid tests, C4, and FGF19, so these were not major considerations in this survey.\u003c\/p\u003e\n\n\u003ch3\u003eWho should have access to SeHCAT testing?\u003c\/h3\u003e\n\n\u003cp\u003eHaving a diagnostic test is one thing; being able to access it is another. The experts were asked about access to SeHCAT, FGF19, C4, and faecal tests in hospitals — all were thought appropriate. However, a striking finding was that only \u003cstrong\u003e50%\u003c\/strong\u003e of experts thought that general practitioners (GPs, i.e., family doctors) should have direct access to SeHCAT testing. It was recognised that both hospitals and GPs would also conduct therapeutic trials.\u003c\/p\u003e\n\n\u003ch3\u003eHow often is SeHCAT used in different clinical situations?\u003c\/h3\u003e\n\n\u003cp\u003eThe survey went beyond simple availability and asked experts how often they would actually request SeHCAT or a therapeutic trial in specific clinical scenarios. The results are detailed in Table 2 of the original paper and summarised below. Experts were asked to classify their use as \"always\" (\u0026gt;99% of the time), \"usually\" (\u0026gt;70%), \"sometimes\" (30–70%), \"rarely\" (\u0026lt;30%), or \"never\" (0%).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFunctional diarrhoea (diarrhoea without significant abdominal pain or bloating, lasting more than 6 months):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eSeHCAT would be requested \u003cstrong\u003eusually\u003c\/strong\u003e (more than 70% of the time) by \u003cstrong\u003e80%\u003c\/strong\u003e of respondents\u003c\/li\u003e\n  \u003cli\u003eA therapeutic trial would be usually used by only \u003cstrong\u003e10%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eThis difference was highly statistically significant (p\u0026lt;0.001), meaning it is extremely unlikely to be due to chance\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eIrritable bowel syndrome with predominant diarrhoea (IBS-D) — more than 25% of stools being Bristol Stool Form Scale (BSFS) type 6\/7 in the last 3 months:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eSeHCAT was usually requested by \u003cstrong\u003e70%\u003c\/strong\u003e of respondents\u003c\/li\u003e\n  \u003cli\u003eThis was significantly more than those who would use a therapeutic trial (p\u0026lt;0.002)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eIBS with mixed bowel habit (more than 25% of stools type 6\/7 and more than 25% type 1\/2):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eSeHCAT was usually requested by \u003cstrong\u003e43%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eAt least sometimes (more than 30% of the time) by \u003cstrong\u003e62%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eRarely used by \u003cstrong\u003e38%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eIBS with constipation (fewer than 25% of stools type 6\/7, more than 25% type 1\/2):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eSeHCAT was rarely used by \u003cstrong\u003e50%\u003c\/strong\u003e of respondents\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003ePostcholecystectomy diarrhoea (diarrhoea starting after gallbladder removal):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eSeHCAT was usually used by \u003cstrong\u003e71%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eA therapeutic trial was usually used by \u003cstrong\u003e36%\u003c\/strong\u003e (p=0.08, a trend but not quite statistically significant)\u003c\/li\u003e\n  \u003cli\u003eWhen including those who would use the test at least sometimes, SeHCAT was significantly more used than a trial (\u003cstrong\u003e90% vs 50%\u003c\/strong\u003e, p=0.02)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCrohn's disease with diarrhoea, ileal resection of 50–100 cm, and negative inflammatory markers:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eA therapeutic trial would be used roughly as often as SeHCAT by about half of respondents\u003c\/li\u003e\n  \u003cli\u003eEither test was considered at least sometimes by at least 70% of respondents\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSame clinical scenario but with raised inflammatory markers (serum C-reactive protein and faecal calprotectin):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eSeHCAT was used by over 50% at least sometimes\u003c\/li\u003e\n  \u003cli\u003eHowever, use of a therapeutic trial was much less likely than when inflammatory markers were negative (p=0.02)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis pattern makes clinical sense: when a patient has active Crohn's disease with clear inflammation, doctors are more cautious about giving treatments before confirming the cause of diarrhoea with a formal test.\u003c\/p\u003e\n\n\u003ch2 id=\"treatment\"\u003eTreatment Decisions and Expected Response Rates\u003c\/h2\u003e\n\n\u003cp\u003eOnce BAD is confirmed, what happens next? The experts were asked about the likelihood of offering treatment (with bile acid sequestrants) based on the patient's SeHCAT result. The results are striking and clinically important.\u003c\/p\u003e\n\n\u003cp\u003eSeHCAT results are reported as the percentage of radioactive bile acid retained at 7 days. Lower retention means more severe bile acid leakage. The expert approach was:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSevere disease (SeHCAT retention 0–5%):\u003c\/strong\u003e All respondents (100%) would \u003cstrong\u003ealways\u003c\/strong\u003e treat these patients\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModerate disease (SeHCAT 5–10%):\u003c\/strong\u003e 86% would always treat; the rest would usually treat\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMild disease (SeHCAT 10–15%):\u003c\/strong\u003e 86% would usually treat\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBorderline (SeHCAT 15–20%):\u003c\/strong\u003e 80% would sometimes offer treatment\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNormal (SeHCAT \u0026gt;20%):\u003c\/strong\u003e Treatment was rarely offered\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003ePredicted response rates to treatment\u003c\/h3\u003e\n\n\u003cp\u003eThe experts were also asked what response rate they would expect following optimisation of bile acid sequestrant (BAS) therapy for each SeHCAT category. The predicted response rate varied inversely with SeHCAT values — meaning the lower the retention, the better the expected response. The full distribution is shown below:\u003c\/p\u003e\n\n\u003cstrong\u003ePredicted percentage response rates to BAS therapy according to SeHCAT result:\u003c\/strong\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSeHCAT 0–5%:\u003c\/strong\u003e 53% of experts predicted ≥90% response; 48% predicted 70–90% response\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSeHCAT 5–10%:\u003c\/strong\u003e 24% predicted ≥90% response; 58% predicted 70–90% response; 14% predicted 50–70%; 5% predicted \u0026lt;30%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSeHCAT 10–15%:\u003c\/strong\u003e 5% predicted ≥90%; 14% predicted 70–90%; 48% predicted 50–70%; 29% predicted 30–50%; 5% predicted \u0026lt;30%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSeHCAT 15–20%:\u003c\/strong\u003e 10% predicted 50–70%; 45% predicted 30–50%; 45% predicted \u0026lt;30%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSeHCAT \u0026gt;20%:\u003c\/strong\u003e 100% of experts predicted a \u0026lt;30% response rate\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn plain terms: patients with the most severe BAD (lowest SeHCAT retention) have the highest likelihood of responding well to treatment. Expected response rates for severe disease exceed 70% in the most affected patients. Even those with mild disease (10–15% retention) have a reasonable chance of improvement, with most experts predicting a 50–70% response rate. This is important encouragement for patients considering testing.\u003c\/p\u003e\n\n\u003ch2 id=\"medications\"\u003eMedication Doses and Administration\u003c\/h2\u003e\n\n\u003cp\u003eBile acid sequestrants (BAS) are the mainstay of treatment for BAD. These medications bind to bile acids in the intestine, preventing them from causing fluid secretion in the colon. The survey provided detailed information about prescribing practices.\u003c\/p\u003e\n\n\u003ch3\u003eWhich medication is used first?\u003c\/h3\u003e\n\n\u003cp\u003e\u003cstrong\u003eColestyramine\u003c\/strong\u003e was the first-line BAS used by \u003cstrong\u003e95%\u003c\/strong\u003e of respondents. This is a powder that is mixed with water or juice. \u003cstrong\u003eColesevelam\u003c\/strong\u003e was the second choice, and \u003cstrong\u003ecolestipol\u003c\/strong\u003e was also mentioned. Colesevelam comes in tablet form, making it more acceptable to many patients, but it remains the second choice. The experts recognised the importance of trying an alternative BAS if the first one produces an incomplete response.\u003c\/p\u003e\n\n\u003ch3\u003eStarting doses for colestyramine\u003c\/h3\u003e\n\n\u003cp\u003eFor a typical patient weighing 70 kg, the starting dose of colestyramine varied considerably among experts:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e29%\u003c\/strong\u003e started at 2 g once daily\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e38%\u003c\/strong\u003e started at 4 g once daily\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e24%\u003c\/strong\u003e started at 4 g twice daily\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e10%\u003c\/strong\u003e started at 4 g three times daily\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eStarting doses for colesevelam\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e29%\u003c\/strong\u003e started at 625 mg once daily\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e24%\u003c\/strong\u003e started at 1.25 g once daily\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e29%\u003c\/strong\u003e started at 1.25 g twice daily\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e10%\u003c\/strong\u003e started at 1.25 g three times daily (or another regimen)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eTiming of medication\u003c\/h3\u003e\n\n\u003cp\u003eThere was a preference to give these drugs \u003cstrong\u003elast thing at night\u003c\/strong\u003e (38% of respondents) rather than with food (29%). This is worth discussing with your doctor if you find your current timing is not working well. Additionally, \u003cstrong\u003e76%\u003c\/strong\u003e of experts usually gave warnings to take other medications \u003cstrong\u003e1 hour before or 4 hours after\u003c\/strong\u003e the BAS, in order to avoid interactions. This is particularly important because bile acid sequestrants can bind to other medications and reduce their absorption.\u003c\/p\u003e\n\n\u003ch3\u003eWhat if the response is incomplete?\u003c\/h3\u003e\n\n\u003cp\u003eMany patients experience some improvement but not complete resolution of symptoms. The experts were unanimous in their approach to this situation. When patients had an incomplete response, the following recommendations were common:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIncreasing the dose\u003c\/strong\u003e – recommended by 100% of respondents\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIncreasing use of drugs such as loperamide\u003c\/strong\u003e (Imodium, an anti-diarrhoeal medication) – recommended by 80%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChanging to an alternative BAS\u003c\/strong\u003e (e.g., colesevelam or colestipol) – recommended by 71%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAdvice on a low-fat diet\u003c\/strong\u003e (40 g\/day) – recommended by 71%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAvoidance of high FODMAP foods\u003c\/strong\u003e – recommended by 29%\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eNotably, there was little difference in these recommendations whether the patient had a SeHCAT result of 3% or 13%. In other words, the same stepwise treatment strategy applies across the range of BAD severity.\u003c\/p\u003e\n\n\u003ch2 id=\"followup\"\u003eFollow-Up and Improving Patient Experience\u003c\/h2\u003e\n\n\u003cp\u003eThe survey also asked about follow-up care for a typical patient being treated with a BAS. The following approaches were given broadly similar importance by the experts:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAnnual review\u003c\/strong\u003e by a specialist (gastroenterologist) or GP\u003c\/li\u003e\n  \u003cli\u003ePatient support groups\u003c\/li\u003e\n  \u003cli\u003eDietetic review (consulting a registered dietitian)\u003c\/li\u003e\n  \u003cli\u003ePharmacist review\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMonitoring of blood vitamins and lipids\u003c\/strong\u003e (because bile acid sequestrants can affect absorption of fat-soluble vitamins and cholesterol levels)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese are practical points that patients can raise at their next appointment. If you are taking a BAS long-term, asking your doctor about annual blood tests for vitamins and lipid levels is a reasonable step.\u003c\/p\u003e\n\n\u003ch3\u003eImproving the overall patient experience\u003c\/h3\u003e\n\n\u003cp\u003eExperts were asked what would most improve the patient experience for people with BAD. The majority considered all of the following important:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGreater recognition of BAD by various professional groups\u003c\/strong\u003e, particularly gastroenterologists\u003c\/li\u003e\n  \u003cli\u003eGreater recognition in the popular press\u003c\/li\u003e\n  \u003cli\u003eGreater recognition by GPs\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eImproved diagnosis\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eImproved drugs\u003c\/strong\u003e for treating the condition\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis reinforces the message that awareness is one of the biggest barriers to patients receiving timely, effective care.\u003c\/p\u003e\n\n\u003ch2 id=\"discussion\"\u003eExpert Discussion: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe experts discuss several important implications of their findings.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFirst, the need for SeHCAT testing is strongly supported.\u003c\/strong\u003e The survey clearly demonstrates that making a formal diagnosis with SeHCAT testing is the preferred approach. Only in one specific patient group — those with Crohn's disease, ileal resection, and negative inflammatory markers — did a therapeutic trial of treatment receive support similar to SeHCAT testing. This makes sense because accumulated data shows that more than 90% of these patients are likely to have an abnormal SeHCAT result. The limited support for therapeutic trials elsewhere indicates that doctors value obtaining a clear diagnosis before starting treatment, rather than simply trying treatment and seeing what happens.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSecond, awareness of BAD in functional bowel disorders is growing.\u003c\/strong\u003e The latest Rome IV guidance (the internationally recognised criteria for diagnosing functional gastrointestinal disorders) now includes consideration of BAD in functional bowel disorders with diarrhoea. The experts in this survey provide concrete data supporting this: they consider SeHCAT testing usually necessary in patients who meet criteria for functional diarrhoea and IBS-D. They also sometimes recommend it for patients with IBS and mixed bowel habits.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThird, there are significant economic advantages to early diagnosis.\u003c\/strong\u003e Recent studies have shown that diagnosing BAD early with SeHCAT testing reduces unnecessary investigations — particularly cross-sectional imaging (such as CT scans), repeated colonoscopies, and unnecessary trials of expensive medications. This is good news for healthcare systems and for patients who might otherwise undergo a long and uncomfortable diagnostic journey.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFourth, the international availability of SeHCAT is a major issue.\u003c\/strong\u003e The rates of BAD are likely similar worldwide, but the SeHCAT test is only available in certain countries and is not licenced in the USA. This has \"greatly impaired the understanding of its value,\" as the authors note, and has hindered recognition of BAD, development of new drugs, and formulation of consensus guidelines. If SeHCAT licensing cannot be extended, alternative tests such as 48-hour faecal bile acid measurements, C4, and FGF19 will require further development and validation. The work at the Mayo Clinic on faecal primary bile acid measurement is an interesting development related to bile acid secretion and absorption.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFifth, there is a role for blood tests in the diagnostic pathway.\u003c\/strong\u003e Previous findings suggest that low C4 and high FGF19 levels both have good negative predictive value (meaning normal results help rule out BAD) and may help select patients for further testing. However, the SeHCAT test has a unique advantage: because it measures retention over 7 days, it integrates multiple cycles of bile acid secretion and reabsorption, making it less affected by day-to-day variation and dietary effects.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinally, treatment approaches are well established.\u003c\/strong\u003e Bile acid sequestrants, particularly colestyramine, are the mainstay of treatment. Good response rates are predicted in patients with severe disease. Starting with a low dose, giving the medication last thing at night, and considering a low-fat diet (40 g\/day) to help reduce symptoms are all recommended strategies. Alternative drug therapies and diets become particularly relevant when the medication supply is interrupted — an issue that many patients have experienced during periods of drug shortage.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\n\u003cp\u003eIt is important to understand the limitations of this research. The study reflects \u003cstrong\u003eopinion only\u003c\/strong\u003e, not direct evidence from clinical trials. It is also limited geographically to the UK, where there is greater use of SeHCAT testing and thus greater experience in BAD diagnosis and management than in most other countries.\u003c\/p\u003e\n\n\u003cp\u003eThere is a possibility that other UK gastroenterologists who were not part of this network may have different views. However, the fact that all respondents had published research on BAD and had diagnosed large numbers of patients (most over 50, nearly half over 100) gives substantial weight to their collective opinion, particularly where there was strong consensus.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, the experts' experience with newer tests (faecal bile acids, C4, FGF19) was limited, so these were not major considerations in the survey. The cost-effectiveness of various diagnostic strategies was also not directly assessed, although the experts note that published studies show economic advantages to early SeHCAT testing.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on this expert survey, here is what patients should know and consider:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you have chronic diarrhoea, don't accept \"it's just IBS\" without exploring further.\u003c\/strong\u003e BAD is a common cause of symptoms in people diagnosed with IBS-D or functional diarrhoea. If you have frequent loose stools (more than 3 times a day), urgency, or faecal incontinence, ask your doctor whether bile acid diarrhoea has been considered.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSeHCAT testing is the gold standard for diagnosis.\u003c\/strong\u003e It is a relatively simple test: you swallow a capsule and have a scan over 7 days. If it is not available at your hospital, ask about blood tests (FGF19, C4) or a therapeutic trial. However, be aware that a formal diagnosis is preferred before starting long-term treatment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you have had your gallbladder removed, prostate or abdominal radiation, ileal surgery, or weight loss surgery, and you now have diarrhoea, BAD is a strong possibility\u003c\/strong\u003e and testing should be considered.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTreatment works.\u003c\/strong\u003e If your SeHCAT test is positive, the chance of improvement with bile acid sequestrant therapy is high — over 70% in the most severely affected patients. Even patients with mild BAD (10–15% retention) have a reasonable chance of improvement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBile acid sequestrants require patience and optimisation.\u003c\/strong\u003e Your doctor may start with a low dose and increase it gradually. If one medication does not work well, ask about switching to another. Taking the medication last thing at night can help. Take other medications either 1 hour before or 4 hours after the BAS to avoid interactions.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eA low-fat diet (around 40 g of fat per day) can help reduce symptoms\u003c\/strong\u003e and is worth discussing with a dietitian, particularly if you have an incomplete response to medication alone.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk for annual follow-up.\u003c\/strong\u003e Long-term monitoring of vitamin levels and lipids is reasonable, and regular review with a specialist, GP, or pharmacist can help optimise your treatment and overall experience.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider patient support groups.\u003c\/strong\u003e These were valued by experts as part of the overall patient experience. Connecting with others who have BAD can provide practical advice and emotional support.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is bile acid diarrhoea (BAD) and why is it often missed?\u003c\/h3\u003e\n\u003cp\u003eBAD occurs when excess bile acids spill into the colon, causing watery diarrhoea, urgency, and incontinence. It is underdiagnosed because symptoms mimic irritable bowel syndrome, and many patients experience delays over five years. Experts recommend considering BAD in anyone with chronic loose stools, especially after gallbladder removal, ileal surgery, or radiation.\u003c\/p\u003e\n\u003ch3\u003eHow is bile acid diarrhoea diagnosed?\u003c\/h3\u003e\n\u003cp\u003eThe SeHCAT test is the preferred diagnostic tool, used by all 21 experts surveyed. You swallow a capsule with a radioactive tracer, and a scan measures retention over 7 days. Retention below 15% confirms BAD. Blood tests (FGF19, C4) and therapeutic trials are also used, but SeHCAT is the gold standard where available.\u003c\/p\u003e\n\u003ch3\u003eWhat symptoms should make me ask my doctor about bile acid diarrhoea?\u003c\/h3\u003e\n\u003cp\u003eExperts would test for BAD if you always have loose stools, pass stools more than 3 times daily, have intermittent loose stools, or experience weekly urgency or faecal incontinence. They would not test based on stool colour alone. If you have these symptoms and a history of gallbladder removal, ileal resection, or IBS-D, ask about BAD.\u003c\/p\u003e\n\u003ch3\u003eHow effective is treatment for bile acid diarrhoea?\u003c\/h3\u003e\n\u003cp\u003eBile acid sequestrants are highly effective. In patients with severe BAD (SeHCAT retention 0–5%), over 70% of experts predicted a 70–90% or higher response. Even mild cases (10–15% retention) had predicted response rates of 50–70%. Treatment requires dose optimisation and sometimes switching medications or adding a low-fat diet.\u003c\/p\u003e\n\u003ch3\u003eWhat is the first-line medication for bile acid diarrhoea and how is it taken?\u003c\/h3\u003e\n\u003cp\u003eColestyramine was the first-line treatment for 95% of experts. It is a powder mixed with water or juice. Starting doses varied, but many prefer giving it last thing at night. If symptoms persist, experts recommend increasing the dose, adding loperamide, switching to colesevelam or colestipol, or trying a 40 g\/day low-fat diet.\u003c\/p\u003e\n\u003ch3\u003eCan bile acid diarrhoea occur after gallbladder removal or other surgeries?\u003c\/h3\u003e\n\u003cp\u003eYes. Experts recognised BAD as associated with cholecystectomy (gallbladder removal), ileal resection, right hemicolectomy, bariatric surgery, and partial gastrectomy. If you develop chronic diarrhoea after any of these procedures, ask your doctor whether BAD testing, such as SeHCAT, is appropriate. Treatment can greatly improve symptoms.\u003c\/p\u003e\n\u003ch3\u003eWhat follow-up care is recommended for people taking bile acid sequestrants?\u003c\/h3\u003e\n\u003cp\u003eExperts support annual review by a specialist or GP, dietetic review, pharmacist review, and monitoring of blood vitamins and lipids, since sequestrants can affect absorption. They also value patient support groups. Ask your doctor about annual blood tests and review appointments to optimise long-term management.\u003c\/p\u003e\n\u003ch3\u003eWhen should a patient with suspected bile acid diarrhoea seek a second opinion?\u003c\/h3\u003e\n\u003cp\u003eIf you have chronic diarrhoea and have been told it is just IBS, or if you have had symptoms for years without a clear diagnosis, a second opinion can help. Experts recommend considering bile acid diarrhoea (BAD) in anyone with frequent loose stools, urgency, or incontinence, especially after gallbladder removal or ileal surgery. The SeHCAT test is the preferred diagnostic tool, and treatment with bile acid sequestrants is effective in over 70% of severe cases. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Diagnosis and management of bile acid diarrhoea\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Julian R F Walters, Ramesh Arasaradnam, H Jervoise N Andreyev, for the UK Bile Acid Related Diarrhoea Network\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e Frontline Gastroenterology, 2020; volume 11, pages 358–363. doi:10.1136\/flgastro-2019-101301\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eReceived:\u003c\/strong\u003e 27 July 2019 | \u003cstrong\u003eRevised:\u003c\/strong\u003e 16 August 2019 | \u003cstrong\u003eAccepted:\u003c\/strong\u003e 2 September 2019 | \u003cstrong\u003ePublished online:\u003c\/strong\u003e 11 September 2019\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c\/strong\u003e The authors declared no specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace individual medical advice. Always consult your healthcare provider about your specific condition and treatment options.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47458879570076,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.es\/products\/understanding-bile-acid-diarrhoea-expert-guidance-on-diagnosis-and-treatment","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}